Introduction
Most people who join regulatory affairs picture submissions: dossiers, modules, agency meetings, approval letters. Fewer picture the work that begins the day after approval, when the commercial team wants to tell the world what the product does. That work belongs to the advertising and promotion regulatory specialist, sometimes called the ad/promo reviewer, promotional regulatory lead, or regulatory member of the promotional review committee.
It is one of the least understood roles in the function and one of the more distinctive. The subject matter is narrow, the pace is fast, and the working relationships are different from anything in submissions work. If you are a submissions person wondering whether the grass is greener, or a newer professional trying to understand what these postings actually want, this is what the job looks like from the inside.
The Core of the Job
Every piece of promotional material a company puts in front of a prescriber, a payer, or a patient has to be consistent with what the regulator approved. The specialist is the person who decides whether a given piece clears that bar before it goes out.
In the United States, prescription drug promotion sits with FDA. Materials for drugs reviewed by CDER fall under the Office of Prescription Drug Promotion; biologics reviewed by CBER fall under the Advertising and Promotional Labeling Branch. The substantive rules live largely in 21 CFR 202.1 and the labeling regulations that sit alongside it, supplemented by a long shelf of guidance documents. Companies also submit promotional pieces to FDA on Form FDA 2253 at the time of initial dissemination, which means the specialist is often the person who owns that submission process as well.
The recurring questions are always some version of the same few:
- Is every efficacy claim supported by substantial evidence, and does it match the approved indication rather than stretching past it?
- Is risk information presented with fair balance, in comparable prominence and readability to the benefit claims?
- Are material facts about the product omitted in a way that makes the piece misleading?
- Does a comparative claim have head-to-head data behind it, or is it comparing across trials that were never designed to be compared?
- Does a graph, a chart, or a patient image imply something the data does not support?
Medical devices work on similar logic through a different door: claims must stay within the cleared or approved indications for use, and the split of jurisdiction between FDA and the Federal Trade Commission depends on the type of device and the type of communication. Outside the United States, the architecture differs again. In the European Union, promotion of medicines is governed through Directive 2001/83/EC as implemented in national law, with industry codes such as the EFPIA framework layered on top, and direct-to-consumer advertising of prescription medicines is prohibited. A specialist supporting global markets spends real time on the fact that a piece cleared in one market may be unusable in another.
The Line Between Promotion and Scientific Exchange
One boundary comes up more than any other, and new specialists tend to underestimate how much of their time it will consume: the difference between promoting a product and exchanging scientific information about it.
Companies communicate about their products in contexts that are not promotional. Responding to an unsolicited request for information from a physician, presenting data at a scientific congress, publishing results, and supporting investigator interactions all sit in different territory from a sales aid. The distinction is real, it is recognized in FDA guidance, and it is also the place where well-intentioned people drift. A medical science liaison discussing data in response to a genuine question is doing one thing; the same conversation, prompted by a sales colleague who arranged it to get around a claim restriction, is doing something else entirely.
The specialist is usually the person who helps the organization keep that line visible. That means reviewing medical information response letters, weighing in on congress materials, advising on how field medical teams are briefed, and occasionally raising an uncomfortable question about why a particular interaction is being routed the way it is. It also means understanding communications about products or indications that are not yet approved, where the constraints are tighter still and the consequences of getting it wrong are larger.
What the Day Actually Looks Like
The rhythm is driven by a review committee. Most companies run a standing cross-functional review, commonly called the promotional review committee or medical, legal and regulatory review. Regulatory, medical affairs, and legal each hold a seat, and material moves through on a fixed cadence, often weekly.
Between meetings, the specialist is reading. A single week can bring a conference booth panel, a sales aid, a set of social posts, a patient brochure, a payer deck, a congress abstract, and a revision of a piece reviewed three weeks ago. Each one arrives annotated, or should, with references tied to specific claims. Much of the job is checking those references: opening the cited paper, finding the actual figure, and confirming the claim on the slide is what the data says rather than a friendlier version of it.
Then comes the part that separates people who last in the role from people who do not: the conversation. A specialist who simply writes rejected in a comment box creates an adversary. A specialist who writes that the claim as drafted goes beyond the indication, and here is a version that says something true and still lands, becomes the person the brand team brings problems to early. That difference is the whole job.
There is also a steady administrative spine. Form 2253 submissions have to go out on time and be tracked. Material has to be version-controlled, because a piece in the field with an expired reference is a live problem. Many companies maintain expiration dates on approved pieces and periodic re-reviews, and someone has to run that calendar.
The Skills That Matter
Close reading. The core competency is noticing the gap between what a sentence says and what the underlying evidence supports. That is a reading skill before it is a regulatory one, and it does not correlate neatly with years of experience.
Comfort with judgment calls. Submissions work has more determinate answers than promotional review does. A great deal of ad/promo sits in territory where reasonable, well-informed people disagree, and the specialist has to take a position, document the reasoning, and be willing to be questioned on it.
Speed under commercial pressure. Congress season and launch windows do not move. The role requires making sound calls quickly, and knowing which questions genuinely need escalation versus which are being escalated because someone did not like the first answer.
Enough clinical literacy to read the source. You do not need to be a statistician, but you need to be able to open a pivotal trial publication and find the endpoint, the population, and the confidence interval without help.
Diplomatic backbone. The role sits between a commercial organization with revenue targets and a regulatory framework that constrains what can be said about the product. Being liked and being effective are not the same thing, and the specialists who thrive have made peace with that.
Who Moves Into It, and Where It Leads
People arrive from several directions. Some come from submissions or labeling work and find the promotional side a natural extension, since labeling is where every claim ultimately traces back to. Some come from medical affairs or medical information, bringing clinical fluency and needing to learn the regulatory frame. Some come from legal or compliance backgrounds. A smaller number come from the commercial side, which can work well when the person genuinely converts rather than trying to be an advocate with a regulatory title.
The path forward tends to run in two directions. One is depth: senior specialist, then lead or associate director for promotional regulatory across a portfolio, then head of promotional review at a larger organization. The other is breadth: using ad/promo as one of several regulatory disciplines on the way to a broader leadership role, on the theory that a regulatory head who has never sat in a promotional review is missing a real part of the picture.
There is also meaningful consulting demand. Smaller companies approaching a first launch frequently do not have anyone who has run a promotional review committee, and they buy that experience by the hour.
What to Watch For Before You Take the Job
Ask how the review committee actually functions. A well-run committee has clear decision rights, a real escalation path, and leadership that backs a defensible no. A poorly run one relegates regulatory to a rubber stamp and calls it partnership. You can learn a lot by asking what happens when regulatory and commercial disagree and who breaks the tie.
Ask about volume and staffing. Promotional review workload scales with the number of brands, the number of markets, and how aggressively the company markets. A single specialist covering several launched brands across multiple channels is a different job from one supporting a single product.
Ask about the company's enforcement history and posture. FDA publishes untitled letters and warning letters concerning promotional communications, and they are public. Reading a few is one of the fastest ways to understand what the agency actually objects to in practice, and asking a hiring manager how the company thinks about that risk tells you a great deal about the culture you would be joining.
Finally, be honest with yourself about the subject matter. This is not a role that touches development strategy or agency negotiation. If what draws you to regulatory affairs is shaping a clinical program or arguing a submission through review, promotional work will feel adjacent to the thing you wanted. If what draws you is the discipline of making sure a claim is true and supportable, this is one of the purest expressions of that instinct in the whole field.
Conclusion
Advertising and promotion regulatory work is a small, specific, and genuinely consequential corner of regulatory affairs. It sits where the science meets the market, it demands judgment more than procedure, and it rewards people who can say no in a way that leaves a working relationship intact. For the right temperament it is one of the more interesting jobs in the function, and it is chronically under-considered by candidates who never learned it existed.